The safety of albiglutide for the treatment of type 2 diabetes (Q39415439)

11 September 2017

1 reference

title

The safety of albiglutide for the treatment of type 2 diabetes (English)

1 reference

11 September 2017

1 reference

Marc S Rendell

1

1 reference

PubMed ID

28678550

11 September 2017

language of work or name

English

0 references

publication date

5 July 2017

1 reference

Expert Opinion on Drug Safety

11 September 2017

1 reference

11 September 2017

16

1 reference

11 September 2017

1089-1097

1 reference

11 September 2017

9

1 reference

The Physiology of Glucagon-like Peptide 1

11 September 2017

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1351538

The biology of incretin hormones

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1351538

Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1351538

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1351538

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1351538

Glucagon-like peptide-1 as a treatment option for type 2 diabetes and its role in restoring beta-cell mass

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1351538

Mechanisms of the incretin effect in subjects with normal glucose tolerance and patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1351538

Adjunctive Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Type 1 Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1351538

Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1351538

Liraglutide: a once-daily incretin mimetic for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1351538

Exenatide efficacy and safety: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1351538

Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1351538

Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1351538

A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1351538

The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1351538

Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1351538

A role for glucagon-like peptide-1 in the central regulation of feeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1351538

Effect of glucagon-like peptide-1 receptor antagonism on appetite and food intake in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1351538

Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1351538

Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1351538

Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1351538

Effects of lixisenatide once daily on gastric emptying in type 2 diabetes--relationship to postprandial glycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1351538

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1351538

Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1351538

Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1351538

Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1351538

Clinical pharmacology of albiglutide, a GLP-1 receptor agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1351538

Incretin physiology and pathophysiology from an Asian perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1351538

Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not contr

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1351538

Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1351538

HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1351538

Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1351538

Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1351538

Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1351538

Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1351538

Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1351538

Albiglutide for the treatment of type 2 diabetes mellitus: An integrated safety analysis of the HARMONY phase 3 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1351538

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1351538

Pancreatic safety of incretin-based drugs--FDA and EMA assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1351538

Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1351538

Response to Comment on Crews et al. Role and Determinants of Adherence to Off-loading in Diabetic Foot Ulcer Healing: A Prospective Investigation. Diabetes Care 2016;39:1371-1377.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1351538

Endogenous GLP1 and GLP1 analogue alter CNS responses to palatable food consumption

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1351538

Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1351538

Activation of the GLP-1 receptors in the nucleus of the solitary tract reduces food reward behavior and targets the mesolimbic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1351538

Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1351538

Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1351538

Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1351538

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1351538

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1351538

The path to approval of new drugs for diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1351538

A randomized dose-finding study demonstrating the efficacy and tolerability of albiglutide in Japanese patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1351538

10.1080/14740338.2017.1351538

21 January 2018

Identifiers

DOI

1 reference

11 September 2017

1 reference

PubMed ID

28678550